Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.41 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.41 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711180 | 0.81 | TRPM2 (0.56) | — | |
| SCHEMBL22918363 | 0.77 | POLB (0.54) | P2RY1P2RX3P2RX1ALDH1A1ENPP1 | |
| SCHEMBL21311195 | 0.74 | EGFR (0.44) | — | |
| SCHEMBL23025515 | 0.73 | ADORA3 (0.53) | SMN1; SMN2 | |
| SCHEMBL25521510 | 0.73 | ADORA3 (0.53) | SMN1; SMN2 | |
| SCHEMBL21311216 | 0.73 | ADORA2A (0.47) | SMN1; SMN2 | |
| SCHEMBL22837903 | 0.73 | TRPM2 (0.46) | — | |
| SCHEMBL21283050 | 0.72 | P2RX3 (0.45) | P2RY1P2RX3P2RX4P2RX2P2RX1 | |
| SCHEMBL21311217 | 0.72 | ADORA2A (0.47) | SMN1; SMN2 | |
| SCHEMBL21311154 | 0.72 | ADORA3 (0.47) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | P2RY1 22/4885P2RX3 78/4885P2RX4 74/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | P2RY1 22/4885P2RX3 78/4885P2RX4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.